Trials / Completed
CompletedNCT01303952
Therapy of Chronic Cold Agglutinin Disease With Eculizumab
Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- University Hospital, Essen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the efficacy and safety of eculizumab in symptomatic or transfusion-dependent patients with untreated or refractory hemolytic cold agglutinin disease(CAD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eculizumab | Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2014-09-01
- Completion
- 2015-06-01
- First posted
- 2011-02-25
- Last updated
- 2017-07-19
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01303952. Inclusion in this directory is not an endorsement.